Finanzen von Jade Biosciences Inc (JBIO)JBIOJade Biosciences Inc

Evaluating the bottom line, Jade Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.80%, provide a clear picture of how effectively JBIO converts its operational activities into shareholder value.

In the context of the broader market, JBIO competes directly with industry leaders such as GLUE and ODTX. With a market capitalization of $937.43M, it holds a leading position in the sector. When comparing efficiency, JBIO's gross margin of N/A stands against GLUE's 100.00% and ODTX's N/A. Such benchmarking helps identify whether Jade Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has a negative EPS of -0.76 for Q2 2026 and a forward P/E ratio of 0, indicating that it is currently unprofitable but may have growth potential.